Immunoassay for detection of SCID (severe combined immunodeficiency) in newborns
Immunoassays are used routinely in NBS as a first-tier screening protocol, therefore the multiplex immunoassay presents as a viable alternative or complement to the TREC assay in detecting SCID.Low cost rapid test (Immunoassay vs. DNA testing)For markets where DNA/TREC Assay testing equipment is not widely available i.e. Brazil, Asia.Additiional markets exist in populations where SCID is prevalent but DNA testing is culturally unacceptable i.e Native Americans
Immunoassay for Newborn screening panel Severe Combined Immunodeficiency (SCID).Alternative test for identifying other T-cell immunodeficiencies
Using the Guthrie specimen, our immunoassay utilizes novel antibodies against CD3 epsilon peptides as a marker for T-cell deficiency. This assay is very promising as a viable alternative or complement to the TREC assay for detecting SCID in a Guthrie specimen.
United States
Inventor: PASS, Kenneth, A. | LINDAU-SHEPARD, Barbara | JANIK, David, K.
Priority Number: WO2011109588A1
IPC Current: A61K003804
Assignee Applicant: Health Research Inc.
Title: NOVEL CD3 EPSILON IMMUNOGENS AND ANTIBODIES | NOUVEAUX IMMUNOGÈNES ET ANTICORPS CD3 EPSILON
Usefulness: NOVEL CD3 EPSILON IMMUNOGENS AND ANTIBODIES | NOUVEAUX IMMUNOGÈNES ET ANTICORPS CD3 EPSILON
Summary: The isolated CD3 ε peptide is useful for diagnosing immunodeficiency, preferably severe combined immunodeficiency and T cell immunodeficiency in patient (all claimed).
Novelty: New isolated cluster of differentiation 3 epsilon peptide, useful for diagnosing immunodeficiency e.g. severe combined immunodeficiency in patient, comprises amino acid sequence
Disease Diagnostic/Treatment
Other Disease
8,569,450
USA
